Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response

Author： Zeuzem Stefan   Poordad Fred  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.26, Iss.7, 2010-07, pp. : 1733-1743

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan

By  

Intervirology, Vol. 50, Iss. 4, 2007-07 ,pp. : 310-315

Karger

Access to resources Recommend Favorite

Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients

By  

Intervirology, Vol. 53, Iss. 3, 2010-01 ,pp. : 146-153

Karger

Access to resources Recommend Favorite

Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?

By  

HEPATOLOGY, Vol. 62, Iss. 2, 2015-08 ,pp. : 660-661

John Wiley & Sons Inc

Access to resources Recommend Favorite

Meta-Analysis: Superior Treatment Response in Asian Patients with Hepatitis C Virus Genotype 6 versus Genotype 1 with Pegylated Interferon and Ribavirin

By  

Intervirology, Vol. 58, Iss. 1, 2015-01 ,pp. : 27-34

Karger

Access to resources Recommend Favorite

Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis

By Sabbatani Sergio   Manfredi Roberto   Marinacci Ginevra   Pavoni Michele   Cristoni Lorenzo   Chiodo Francesco  

Scandinavian Journal of Infectious Diseases, Vol. 38, Iss. 3, 2006-03 ,pp. : 205-208

Informa Healthcare

Access to resources Recommend Favorite